Conference Coverage (12th World AIDS)

Vaccinia-Based AIDS Vaccine Safe In Early Trials

Published in AIDS Weekly, August 24th, 1998

A live, recombinant vaccinia virus that expresses multiple HIV antigens is well tolerated by humans, early trial results show.

The vaccine, dubbed TBC-3B by manufacturer Therion Biologics Corp., expresses the HIV env, gag, and pol genes. The trial enrolled 36 HIV negative volunteers who received the vaccine (or vaccinia placebo) either via scarification, intradermal injection, or subcutaneous injection.

"TBC-3B administered by [the various routes] to vaccinia-naive, HIV negative volunteers is well tolerated, even when given as a 100 times higher dose boost," reported Michael C. Keefer of the National Institutes of Health.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-08-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry